Dietary abscisic acid ameliorates influenza-virus-associated disease and pulmonary immunopathology through a PPARγ-dependent mechanism

Journal of Nutritional Biochemistry

Volumn 24, Issue 6, 2013, Pages 1019-1027

  Hontecillas, Raquel ^a   Roberts, Paul C ^b   Carbo, Adria ^a   Vives, Cristina ^a   Horne, William T ^a   Genis, Sandra ^a   Velayudhan, Binu ^b   Bassaganya Riera, Josep ^a,b  

^a VIRGINIA BIOINFORMATICS INSTITUTE   (United States)

^b VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

Abscisic acid; Influenza; LANCL2; PPAR ; Pulmonary inflammation

Indexed keywords

ABSCISIC ACID; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE MARROW CELL; CELL INFILTRATION; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE ACTIVITY; DRUG EFFICACY; EPITHELIUM CELL; GENE EXPRESSION; HEMATOPOIETIC CELL; HISTOPATHOLOGY; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOREGULATION; INFLUENZA; INFLUENZA VIRUS A H3N2; LEUKOCYTE; LUNG ALVEOLUS EPITHELIUM; LUNG LAVAGE; LUNG LESION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RESPIRATORY TRACT MUCOSA; SURVIVAL RATE; UPREGULATION; VIRUS PNEUMONIA; VIRUS REPLICATION; WEIGHT REDUCTION;

ABSCISIC ACID; ANIMALS; ANTI-INFLAMMATORY AGENTS; CHEMOKINE CCL2; DIET; EPITHELIAL CELLS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INTERLEUKIN-10; LEUKOCYTES; LUNG; MICE; MICE, KNOCKOUT; MYELOID CELLS; ORTHOMYXOVIRIDAE INFECTIONS; PNEUMONIA; PPAR GAMMA; RESPIRATORY MUCOSA; VIRUS REPLICATION;

MUS; ORTHOMYXOVIRIDAE;

EID: 84878015761     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2012.07.010     Document Type: Article

References (51)

1. Peiris J.S., Hui K.P., Yen H.L. Host response to influenza virus: protection versus immunopathology. Curr Opin Immunol 2010, 22:475-481.
2. Fedson D.S. Pandemic influenza: a potential role for statins in treatment and prophylaxis. Clin Infect Dis 2006, 43:199-205.
3. Fedson D.S. Confronting an influenza pandemic with inexpensive generic agents: can it be done?. Lancet Infect Dis 2008, 8:571-576.
4. Fedson D.S. Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: why they are needed and how they might work. Influenza Other Respi Viruses 2009, 3:129-142.
5. de Jong M.D., Simmons C.P., Thanh T.T., et al. Fatal outcome of human influenza a (h5n1) is associated with high viral load and hypercytokinemia. Nat Med 2006, 12:1203-1207.
6. Kash J.C., Tumpey T.M., Proll S.C., et al. Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature 2006, 443:578-581.
7. Gill J.R., Sheng Z.M., Ely S.F., et al. Pulmonary pathologic findings of fatal 2009 pandemic influenza a/h1n1 viral infections. Arch Pathol Lab Med 2010, 134:235-243.
8. Szretter K.J., Gangappa S., Lu X., et al. Role of host cytokine responses in the pathogenesis of avian h5n1 influenza viruses in mice. J Virol 2007, 81:2736-2744.
9. Le Goffic R., Balloy V., Lagranderie M., et al. Detrimental contribution of the toll-like receptor (TLR)3 to influenza a virus-induced acute pneumonia. PLoS Pathog 2006, 2:e53.
10. Lin K.L., Suzuki Y., Nakano H., Ramsburg E., Gunn M.D. Ccr2+ monocyte-derived dendritic cells and exudate macrophages produce influenza-induced pulmonary immune pathology and mortality. J Immunol 2008, 180:2562-2572.
11. Wareing M.D., Lyon A., Inglis C., Giannoni F., Charo I., Sarawar S.R. Chemokine regulation of the inflammatory response to a low-dose influenza infection in ccr2-/- mice. J Leukoc Biol 2007, 81:793-801.
12. Zheng B.J., Chan K.W., Lin Y.P., et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza a/h5n1 virus. Proc Natl Acad Sci U S A 2008, 105:8091-8096.
13. Aldridge J.R., Moseley C.E., Boltz D.A., et al. TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. Proc Natl Acad Sci U S A 2009, 106:5306-5311.
14. Budd A., Alleva L., Alsharifi M., et al. Increased survival after gemfibrozil treatment of severe mouse influenza. Antimicrob Agents Chemother 2007, 51:2965-2968.
15. Cloutier A., Marois I., Cloutier D., Verreault C., Cantin A.M., Richter M.V. The prostanoid 15-deoxy-delta12,14-prostaglandin-j2 reduces lung inflammation and protects mice against lethal influenza infection. J Infect Dis 2012, 205:621-630.
16. Harmon G.S., Lam M.T., Glass C.K. Ppars and lipid ligands in inflammation and metabolism. Chem Rev 2011, 111:6321-6340.
17. Straus D.S., Glass C.K. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol 2007, 28:551-558.
18. Straus D.S., Pascual G., Li M., et al. 15-Deoxy-delta 12,14-prostaglandin j2 inhibits multiple steps in the NF-kappa b signaling pathway. Proc Natl Acad Sci U S A 2000, 97:4844-4849.
19. Bassaganya-Riera J., Guri A.J., Lu P., et al. Abscisic acid regulates inflammation via ligand-binding domain-independent activation of PPAR gamma. J Biol Chem 2010, 286:2504-2516.
20. Guri A.J., Misyak S.A., Hontecillas R., et al. Abscisic acid ameliorates atherosclerosis by suppressing macrophage and cd4(+) t cell recruitment into the aortic wall. J Nutr Biochem 2010, [In press].
21. Bassaganya-Riera J., Reynolds K., Martino-Catt S., et al. Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroenterology 2004, 127:777-791.
22. Hontecillas R., Horne W.T., Climent M., et al. Immunoregulatory mechanisms of macrophage PPAR-gamma in mice with experimental inflammatory bowel disease. Mucosal Immunol 2011, 4:304-313.
23. Guri A.J., Hontecillas R., Si H., Liu D., Bassaganya-Riera J. Dietary abscisic acid ameliorates glucose tolerance and obesity-related inflammation in db/db mice fed high-fat diets. Clin Nutr 2007, 26:107-116.
24. Guri A.J., Hontecillas R., Bassaganya-Riera J. Abscisic acid ameliorates experimental IBD by downregulating cellular adhesion molecule expression and suppressing immune cell infiltration. Clin Nutr 2010, 29:824-831.
25. Guri A.J., Evans N.P., Hontecillas R., Bassaganya-Riera J. T cell PPAR gamma is required for the anti-inflammatory efficacy of abscisic acid against experimental IBD. J Nutr Biochem 2010, In press.
26. Herbert A.S., Heffron L., Sundick R., Roberts P.C. Incorporation of membrane-bound, mammalian-derived immunomodulatory proteins into influenza whole virus vaccines boosts immunogenicity and protection against lethal challenge. Virol J 2009, 6:42.
27. Reed L.J., Muench H. A simple method of estimating fifty percent end points. Am J Hyg 1938, 27:493-497.
28. Becker J., Delayre-Orthez C., Frossard N., Pons F. Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases?. Fundam Clin Pharmacol 2006, 20:429-447.
29. Guri A.J., Hontecillas R., Bassaganya-Riera J. Abscisic acid synergizes with rosiglitazone to improve glucose tolerance and down-modulate macrophage accumulation in adipose tissue: possible action of the cAMP/PKA/PPAR gamma axis. Clin Nutr 2010, 29:646-653.
30. Guri A.J., Hontecillas R., Ferrer G., et al. Loss of PPAR gamma in immune cells impairs the ability of abscisic acid to improve insulin sensitivity by suppressing monocyte chemoattractant protein-1 expression and macrophage infiltration into white adipose tissue. J Nutr Biochem 2008, 19:216-228.
31. Cui Y., Miyoshi K., Claudio E., et al. Loss of the peroxisome proliferation-activated receptor gamma (PPARgamma ) does not affect mammary development and propensity for tumor formation but leads to reduced fertility. J Biol Chem 2002, 277:17830-17835.
32. Bassaganya-Riera J., Guri A.J., Lu P., et al. Abscisic acid regulates inflammation via ligand-binding domain-independent activation of PPAR gamma. J Biol Chem 2011, 286:2504-2516.
33. Garcia-Sastre A., Biron C.A. Type 1 interferons and the virus-host relationship: a lesson in detente. Science 2006, 312:879-882.
34. Teijaro J.R., Walsh K.B., Cahalan S., et al. Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell 2011, 146:980-991.
35. Steinberg B.E., Goldenberg N.M., Lee W.L. Do viral infections mimic bacterial sepsis? The role of microvascular permeability: a review of mechanisms and methods. Antiviral Res 2012, 93:2-15.
36. Goldenberg N.M., Steinberg B.E., Slutsky A.S., Lee W.L. Broken barriers: a new take on sepsis pathogenesis. Sci Transl Med 2011, 3:88ps25.
37. Adachi M., Matsukura S., Tokunaga H., Kokubu F. Expression of cytokines on human bronchial epithelial cells induced by influenza virus a. Int Arch Allergy Immunol 1997, 113:307-311.
38. Smith M.R., Standiford T.J., Reddy R.C. Ppars in alveolar macrophage biology. PPAR Res 2007, 2007:23812.
39. Szatmari I., Torocsik D., Agostini M., et al. Ppargamma regulates the function of human dendritic cells primarily by altering lipid metabolism. Blood 2007, 110:3271-3280.
40. Gogolak P., Rethi B., Szatmari I., et al. Differentiation of CD1a- and CD1a+ monocyte-derived dendritic cells is biased by lipid environment and PPARgamma. Blood 2007, 109:643-652.
41. Serhan C.N. The resolution of inflammation: the devil in the flask and in the details. FASEB J 2011, 25:1441-1448.
42. Cilloniz C., Pantin-Jackwood M.J., Ni C., et al. Molecular signatures associated with mx1-mediated resistance to highly pathogenic influenza virus infection: mechanisms of survival. J Virol 2012, 86:2437-2446.
43. Stables M.J., Gilroy D.W. Old and new generation lipid mediators in acute inflammation and resolution. Prog Lipid Res 2011, 50:35-51.
44. Sobrado M., Pereira M.P., Ballesteros I., et al. Synthesis of lipoxin a4 by 5-lipoxygenase mediates PPARgamma-dependent, neuroprotective effects of rosiglitazone in experimental stroke. J Neurosci 2009, 29:3875-3884.
45. Sun J., Madan R., Karp C.L., Braciale T.J. Effector t cells control lung inflammation during acute influenza virus infection by producing IL-10. Nat Med 2009, 15:277-284.
46. Sekine K., Fujishima S., Sasaki J., Ishizaka A., Aiso S., Aikawa N. In vivo IL-18 supplementation ameliorates lethal acute lung injury in burn-primed endotoxemic mice: a novel anti-inflammatory role of IL-18. Shock 2009, 32:554-562.
47. van Zoelen M.A., Verstege M.I., Draing C., et al. Endogenous MCP-1 promotes lung inflammation induced by lps and lta. Mol Immunol 2011, 48:1468-1476.
48. Kobasa D., Jones S.M., Shinya K., et al. Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 2007, 445:319-323.
49. Lipatov A.S., Andreansky S., Webby R.J., et al. Pathogenesis of Hong Kong h5n1 influenza virus ns gene reassortants in mice: the role of cytokines and b- and t-cell responses. J Gen Virol 2005, 86:1121-1130.
50. Garigliany M.M., Habyarimana A., Lambrecht B., et al. Influenza a strain-dependent pathogenesis in fatal h1n1 and h5n1 subtype infections of mice. Emerg Infect Dis 2010, 16:595-603.
51. Palamara A.T., Nencioni L., Aquilano K., et al. Inhibition of influenza a virus replication by resveratrol. J Infect Dis 2005, 191:1719-1729.